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background:  All current renal denervation systems treat the nerves that parallel the renal arteries. The natural orifice denervation system 
developed by Verve Medical directs radiofrequency energy to the renal pelvic space where the preponderance of afferent nerves originate 
and are closely accessible. We have previously presented our early porcine studies utilizing the “Verve Medical NephroBlate™” which 
demonstrated the feasibility of this technique.
methods:  Following our preclinical studies, we developed a protocol to treat a small number of patients (n=3, 4 kidneys) undergoing 
elective nephrectomy. After patient informed consent we treated three patients with end stage kidney disease on the affected diseased 
kidney. One patient was pre-renal transplant and had both kidneys treated. One week after cystoscope aided transurethral treatment with 
the Verve device, the previously planned nephrectomy was performed. Following completion of these patients we treated patients with 
resistant hypertension.
results:  Pre-Nephrectomy Patients -- Procedure time was between 9 to 15 min. The procedures were well tolerated and no adverse 
effects were recorded. The histopathological results of the treated kidney in all cases showed a significant destruction of the peri-pelvic 
nerves from the renal pelvic space to the serosa (1.75mm). We then proceeded with our clinical studies on resistant hypertensive patients. 
Resistant Hypertensive Patients -- Inclusion criteria: Office systolic blood pressure (SBP) ≥ 160 mmHg (SBP ≥ 150 mmHg with Type II 
diabetes mellitus), on >2 antihypertensive agents. BP: Ave 172 mmHg; eGFR: Ave 82.4* ml/min/1.7; Creatinine: Ave 1.03* ml/dL (Ave 
without ESRD subject data). BP Results in Resistant Hypertensive Patients -- Within 30 seconds of treatment of the first kidney, a blood 
pressure response was noted (SYS Mean 44mmHg, D Mean 13mmHg). Following the procedure, none of the patients had significant pain, 
bleeding or urologic issues.
Conclusion:  In this small series of patients treated with 3-month follow-up, they continue to be normotensive and this treatment results in 
an immediate blood pressure response and may be an alternative for treatment of resistant hypertension.
